Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada.
The company use its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing CCNE1-SL inhibitor, a proprietary drug discovery program for tumors with amplification of CCNE1; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was founded in 2016 and is headquartered in Montréal, Canada. The company trades on NASDAQ exchange. The company headquarter is located in Montreal, Canada. The company was established in the 2016.
| Ticker | RPTX |
| Long Name | Repare Therapeutics Inc. |
| Short Name | Repare Therapeutics |